Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001079973-13-000643
Filing Date
2013-11-07
Accepted
2013-11-07 08:12:33
Documents
10
Period of Report
2013-09-30

Document Format Files

Seq Description Document Type Size
1 FORM 10-Q FOR THE PERIOD ENDED 9/30/2013 appy_10q-093013.htm 10-Q 640649
2 EXHIBIT 31.1 ex31x1.htm EX-31.1 12569
3 EXHIBIT 31.2 ex31x2.htm EX-31.2 12412
4 EXHIBIT 32 ex32.htm EX-32 10075
  Complete submission text file 0001079973-13-000643.txt   4926464

Data Files

Seq Description Document Type Size
5 XBRL INSTANCE FILE appy-20130930.xml EX-101.INS 702071
6 XBRL SCHEMA FILE appy-20130930.xsd EX-101.SCH 42424
7 XBRL CALCULATION FILE appy-20130930_cal.xml EX-101.CAL 36025
8 XBRL DEFINITION FILE appy-20130930_def.xml EX-101.DEF 166130
9 XBRL LABEL FILE appy-20130930_lab.xml EX-101.LAB 569222
10 XBRL PRESENTATION FILE appy-20130930_pre.xml EX-101.PRE 271355
Mailing Address 1585 S. PERRY STREET CASTLE ROCK CO 80104
Business Address 1585 S. PERRY STREET CASTLE ROCK CO 80104 (303) 794-2000
Venaxis, Inc. (Filer) CIK: 0001167419 (see all company filings)

EIN.: 841553387 | State of Incorp.: CO | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-33675 | Film No.: 131198536
SIC: 2835 In Vitro & In Vivo Diagnostic Substances